These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10383310)

  • 1. Dracula's wish.
    Peters R; Sikorski R
    Science; 1999 May; 284(5418):1294. PubMed ID: 10383310
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
    Hérault JP; Bernat A; Gaich C; Herbert M
    Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
    Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
    Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SR123781A, a synthetic heparin mimetic.
    Herbert JM; Hérault JP; Bernat A; Savi P; Schaeffer P; Driguez PA; Duchaussoy P; Petitou M
    Thromb Haemost; 2001 May; 85(5):852-60. PubMed ID: 11372679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid two-step synthesis of mitrin from heparosan: a replacement for heparin.
    Kuberan B; Beeler DL; Lawrence R; Lech M; Rosenberg RD
    J Am Chem Soc; 2003 Oct; 125(41):12424-5. PubMed ID: 14531682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct thrombin inhibitors (part 1 of 2).
    Arora UK; Dhir M
    J Invasive Cardiol; 2005 Jan; 17(1):34-8. PubMed ID: 15640538
    [No Abstract]   [Full Text] [Related]  

  • 7. [Synthesis of low molecular weight mimetics of heparin].
    Krylov VB; Ustiuzhanina NE; Nifant'ev NE
    Bioorg Khim; 2011; 37(6):745-79. PubMed ID: 22497075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological properties of synthetic glycoconjugate mimics of heparin comprising different molecular spacers.
    Dreef-Tromp CM; Basten JE; Broekhoven MA; van Dinther TG; Petitou M; van Boeckel CA
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2081-6. PubMed ID: 9873490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design of synthetic heparin analogues with tailor-made coagulation factor inhibitory activity.
    Grootenhuis PD; Westerduin P; Meuleman D; Petitou M; van Boeckel CA
    Nat Struct Biol; 1995 Sep; 2(9):736-9. PubMed ID: 7552742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic low-molecular weight thrombin inhibitors: the ideal antithrombotic drug? An introduction.
    Stürzebecher J; Meier J
    J Enzyme Inhib; 1995; 9(1):1-2. PubMed ID: 8568561
    [No Abstract]   [Full Text] [Related]  

  • 11. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
    Melo FR; Mourão PA
    Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet activation with unfractionated heparin at therapeutic concentrations and comparison with low-molecular-weight heparin and with a direct thrombin inhibitor.
    Cella G; Girolami A; Sasahara AA
    Circulation; 1999 Jun; 99(25):3323. PubMed ID: 10385510
    [No Abstract]   [Full Text] [Related]  

  • 13. Prolonged bleeding time induced by anticoagulant glycosaminoglycans in dogs is associated with the inhibition of thrombin-induced platelet aggregation.
    Kitazato K; Kitazato KT; Sasaki E; Minamiguchi K; Nagase H
    Thromb Res; 2003; 112(1-2):83-91. PubMed ID: 15013278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sugars slide into heparin activity.
    Sinaÿ P
    Nature; 1999 Apr; 398(6726):377-8. PubMed ID: 10201366
    [No Abstract]   [Full Text] [Related]  

  • 15. A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next?
    Petitou M; van Boeckel CA
    Angew Chem Int Ed Engl; 2004 Jun; 43(24):3118-33. PubMed ID: 15199558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion of a polysaccharide to nitric oxide-releasing form. Dual-mechanism anticoagulant activity of diazeniumdiolated heparin.
    Saavedra JE; Mooradian DL; Mowery KA; Schoenfisch MH; Citro ML; Davies KM; Meyerhoff ME; Keefer LK
    Bioorg Med Chem Lett; 2000 Apr; 10(8):751-3. PubMed ID: 10782678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interindividual variability of in vitro response to anticoagulants.
    Samama MM
    Thromb Res; 2011 Jan; 127(1):1. PubMed ID: 21075429
    [No Abstract]   [Full Text] [Related]  

  • 19. Higher concentrations of heparin and hirudin are required to inhibit thrombin generation in tissue factor-activated cord plasma than in adult plasma.
    Baier K; Cvirn G; Fritsch P; Köstenberger M; Gallistl S; Leschnik B; Muntean W
    Pediatr Res; 2005 May; 57(5 Pt 1):685-9. PubMed ID: 15718352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors.
    Coburn CA; Rush DM; Williams PD; Homnick C; Lyle EA; Lewis SD; Lucas BJ; Di Muzio-Mower JM; Juliano M; Krueger JA; Vastag K; Chen IW; Vacca JP
    Bioorg Med Chem Lett; 2000 May; 10(10):1069-72. PubMed ID: 10843219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.